Ankita Das

Ankita Das

Auto-generated profile, based on publicly available information

Ankita Das

Department of Surgical Oncology, Breast Services, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in The Breast Journal
Verified
Journal Article
Open access
ASAnkita Das Sheth
Ankita Das Sheth
SJShalaka Joshi
Shalaka Joshi
AKArul Kumar
Arul Kumar
NNNita Nair
Nita Nair
TSTanuja Shet
Tanuja Shet
RBRajendra Badwe
Rajendra Badwe
Introduction: Idiopathic granulomatous mastitis (IGM) is a benign, chronic inflammatory disease with no effective treatment and high relapse rate. The pathophysiology is poorly understood. Tinosporin, an immunomodulator obtained from Tinospora cordifolia , is known to be useful in treating immune‐mediated diseases. We report our experience of using Tinosporin for IGM and the effectiveness of this “steroid‐free” regimen. Methods: We analysed the clinicopathological characteristics of patients diagnosed with IGM on histopathology during January 2018 and December 2022. Tinosporin tablet (500 mg Guduchi stem extract) was prescribed for 3–6 months; data were collected from electronic medical records and analysed in SPSS v‐29. Results: Of 315 patients, 132 had complete clinical records. Median age was 39 years (25–77), and 107 (81.7%) were premenopausal. Seventy‐eight (59.09%) had clinical suspicion of malignancy. On imaging, 84 (63.64%) were BIRADS 4/5 lesions. Empirical broad‐spectrum antibiotics were prescribed to 101 patients. Tinosporin tablets were prescribed to 91 patients. Symptomatic response was seen in 72 (79.12%). Five patients did not achieve response, while 14 patients (15.38%) were lost to follow‐up. At a median follow‐up of 36 months (14–62 months), only 2 patients on Tinosporin had recurrence. None of the patients needed surgical intervention other than diagnostic biopsy or control of infection, and none received steroids. Conclusion: IGM is a benign, often self‐limiting disorder. However, it mimics malignancy in 60% cases, and histology clinches the diagnosis. We report the efficacy of steroid‐free management of IGM with immunomodulatory herbal origin phytopharmaceutical drug Tinosporin. It is safe, inexpensive and effective. Large volume excisions or mastectomies can be reserved for severe and refractory cases.

28 June 2023 in Clinical Breast Cancer
Verified
Journal Article
Closed access
NNNita S. Nair
Nita S. Nair
ADAnkita Das
Ankita Das
TSTanuja Shet
Tanuja Shet
KKKarishma Kirti
Karishma Kirti
RHRohini Hawaldar
Rohini Hawaldar
RBRa Badwe
Ra Badwe


21 October 2023 in Asian Pacific Journal of Cancer Care
Verified
Journal Article
Open access
PDF file
ADAbhinandan Das
Abhinandan Das
AKApurba Kumar Kalita
Apurba Kumar Kalita
MBMouchumee Bhattacharyya
Mouchumee Bhattacharyya
JNJyotiman Nath
Jyotiman Nath
YYYanpothung Yanthan
Yanpothung Yanthan
MSMongal Sonar
Mongal Sonar
Background: Esophageal cancer is a highly aggressive malignancy often associated with a poor prognosis because of locoregional failure and distant metastases. About 60–70 percent of the patients present at an advanced stage, have a median survival in the range of 6-10 months, and are not amenable to definitive treatment. Dysphagia is the most common complaint, seen in 80%–90% of patients. The priority for managing patients with advanced disease is dysphagia control, which in turn can improve nutritional intake and quality of life. External-beam radiotherapy (EBRT) is one of the major means of palliation. Objective: The primary goal of our study was to assess the efficacy of external beam radiotherapy in alleviating dysphagia in patients with esophageal cancer.Materials and method: This was a single arm prospective clinical study conducted in a tertiary care hospital in northeast India. The study comprised of 57 esophageal cancer patients, ineligible for definitive treatment. The patients received EBRT of 30 Gy in 10 fractions over two weeks. Dysphagia was graded using Modified Takita’s grading system. Patients were followed up at one-month intervals after treatment to assess dysphagia and acute toxicity. Results: Out of 57 patients in the study, subjective dysphagia relief was seen in 82.45%. The median dysphagia score decreased from 3 to 2 at the end of the 3-month post treatment period. (p < .001). In terms of treatment-related toxicity, treatment was well tolerated. No grade 4-5 toxicity was encountered. The most commonly encountered toxicity was radiation esophagitis, which affected 15 patients (26.31%).Conclusion: Radiation significantly improves dysphagia in esophageal cancer patients. It is an effective, non-invasive, and well-tolerated way to treat dysphagia in selected individuals with incurable esophageal cancer.

31 May 2023 in Asian Pacific Journal of Cancer Care
Verified
Journal Article
Open access
PDF file
MSMongal Sonar
Mongal Sonar
MBMouchumee Bhattacharyya
Mouchumee Bhattacharyya
MSMoirangthem Nara Singh
Moirangthem Nara Singh
YYYanpothung Yanthan
Yanpothung Yanthan
MNMoniprom Neog
Moniprom Neog
PSPrashasti Sharma
Prashasti Sharma
Background: Patients with advanced head and neck cancers typically succumb to uncontrolled local disease. Even with aggressive therapy, median survival is about 12 months, and the five-year overall survival <20%. Radiation treatment used in palliative setting is an option for some patients who are not eligible for curative therapy. Palliative treatment aims to reduce cancer-related symptoms while causing the fewest side effects and toxicities as possible. Materials and Methods: After approval from the institutional ethical committee, a prospective randomised study was conducted on squamous cell carcinomas of locally advanced head and neck cancer patients treated with palliative radiotherapy. A total of 62 patients were chosen and randomly assigned (1:1) to one of two treatment groups. Patients in Arm-A received 40 Gy in 16 fractions of radiation therapy, while those in Arm-B received 30 Gy in 10 fractions. The primary goal was to evaluate the subjective responses in both arms, including pain, dysphagia, and bleeding. Results: Mean pain score after completion of radiotherapy was 4.69 and 3.65 in Arm-A and Arm-B respectively, with significant p-value of <0.001. The mean pain score 3 months after completion of treatment was 2.39 and 3.61 in Arm-A and Arm-B respectively, with significant p-value of <0.001. Comparing both the arms dysphagia relief at completion of treatment was higher in Arm-B compared to Arm- A with mean scores of 1.95 and 2.03 which was not significant. After 3 months, it was higher in Arm-A compared to Arm-B, which was also insignificant, while Arm A patients received significant relieve from dysphagia at completion of treatment and during follow-ups. Bleeding was not a significant factor in both the arms. Conclusion: Our study found for immediate pain relief, 30Gy/10 fractions was better, but for long-term relief, 40Gy/16 fractions was better. Alleviation of swallowing difficulties was seen in both regimens.